TAK-743-4008
Completed
A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in Argentina
Clinicaltrials.gov
#NCT04955964About this clinical trial
The main aim of this study is to learn about the safety profile of lanadelumab in teenagers and adults with hereditary angioedema (HAE) in Argentina as part of routine routine practice. This study is about collecting data only. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. The study will collect data from the participant's medical records. Participants do not need to visit their doctor in addition to their normal visits.
AR
Observational clinical trial.
At a glance
What medical conditions were being studied?
Hereditary Angioedema (HAE)
How many participants were enrolled?
48
Were placebos part of the clinical trial?
No
When was the clinical trial conducted?
Jul 2021 - Aug 2023
How long was participation in the clinical trial?
Participants will stay in the study for about 24 weeks.
Key requirements
Sex
All
Age
12+ years
Healthy volunteers?
No
Entry criteria
Boys, girls, men, and women can take part.
Must 12 years or older.
Must have been diagnosed with hereditary angioedema (HAE).
Must have been treated with lanadelumab at least once.
Additional entry criteria will be discussed with the study doctor.